Inflammatory Myopathy Clinical Trial
Official title:
Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy
This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) on idiopathic inflammatory myopathy (IIM).
The investigators designed a single center, open-label, prospective study. Adults with active IIM will be enrolled. IIM is defined as Dermatomyositis (DM) or Polymyositis (PM), meeting the Bohan & Peter (1975) diagnostic criteria for definite or probable DM or PM. One million units of Recombinant Human Interleukin-2 (rhIL-2) was administered subcutaneously every other day for 3 months. All patients were followed up for 3 months after withdraw of IL-2. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06420154 -
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
|
Early Phase 1 | |
| Recruiting |
NCT05859997 -
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
|
N/A | |
| Completed |
NCT03786913 -
Quantitative Muscle Ultrasound as a Marker of Progression in Children With Muscular Diseases
|
||
| Recruiting |
NCT04530461 -
Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
|
||
| Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
| Not yet recruiting |
NCT04237987 -
Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy
|
Phase 2 | |
| Not yet recruiting |
NCT05982041 -
Adult Idiopathic Inflammatory Myopathy With Cardiac Injury
|
||
| Active, not recruiting |
NCT04687111 -
Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
|
Phase 2 | |
| Not yet recruiting |
NCT06379646 -
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
|
N/A | |
| Recruiting |
NCT06373081 -
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
|
N/A |